Our life sciences industry clients range from start-ups to emerging biotechs to established global pharmaceutical companies, as well as the venture capital, private equity, and investment banking firms focused on the life sciences industry. Our lawyers represent life sciences industry clients in mission-critical transactions, such as collaborations, corporate partnering, financing, and M&A.
Our team helps life sciences clients build, negotiate, and implement essential strategic alliances with other pharmaceutical, biotechnology, and diagnostic companies. These transactions are essential to a company’s growth—aiding in the research, development, and commercialization of new products, as well as enabling clients to share risks and rewards, experience, and IP.
Transactions range from early-stage research platform deals to co-development and co-commercialization collaborations to co-promotion arrangements. In the course of structuring and negotiating this range of life science deals, our lawyers provide a variety of legal services, including IP, FDA/regulatory, real estate, tax, litigation prevention, and US and international governmental regulation. In addition, we assist clients with operational matters such as supply, distribution, and equity investment agreements.
We also represent academic institutions and industry partners in licensing technology and sponsoring research programs.
Our team advises private equity and venture capital firms on fund formation and other investment vehicles, and counsels pharmaceutical clients on their participation in these funds and formation of in-house funds.
In connection with M&A transactions, we counsel life science clients on product-related M&A as well as securities-related aspects of public and private mergers, divestitures, and joint ventures. We handle transactions of varying sizes, up to more than $50 billion, and of different types, including negotiated-purchases and divestitures, tender offers, proxy contests, restructurings, leveraged buyouts, and going private transactions. We also represent investment banks and commercial banks, venture capital firms, institutional lenders, independent directors committees, and management groups in M&A matters.